RBC Capital Starts Climb Bio (CLYM) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CLYM Hot Sheet
Price: $10.19 --0%
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 15 | New: 26
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 15 | New: 26
Join SI Premium – FREE
RBC Capital initiates coverage on Climb Bio (NASDAQ: CLYM) with a Outperform rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Climb Bio click here. For more ratings news on Climb Bio click here.
Shares of Climb Bio closed at $11.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Asset Entities Inc (ASST) PT Raised to $43 at StoneX
- Dollar Tree (DLTR) PT Lowered to $159 at JPMorgan
- Bimergen Energy files for Texas retail electricity provider license
Create E-mail Alert Related Categories
New CoverageRelated Entities
RBC Capital, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
